Form 4: Pfizer Executive Michael McDermott Reports Acquisition of Stock Appreciation Rights

Executive Vice President Michael McDermott reported the acquisition of stock appreciation rights (SARs) tied to Pfizer common stock.

Summary

• Michael McDermott, an Executive Vice President at Pfizer, filed a Form 4 with the SEC.
• The filing reports the acquisition of stock appreciation rights (SARs) on February 27, 2024.
• McDermott acquired 125,347 SARs that will be settled in Pfizer common stock on February 27, 2029, subject to vesting requirements.
• He also acquired 110,756 SARs that will be settled in Pfizer common stock on February 27, 2031, subject to vesting requirements.
• The exercise price for both sets of SARs is $26.89.
• Following the reported transactions, McDermott directly owns 125,347 and 110,756 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of executive compensation. The acquisition of SARs could be seen as a positive sign of confidence, but it's not a major event.

Positives

• The acquisition of stock appreciation rights by a high-ranking executive could be interpreted as a sign of confidence in the company's future performance.

Future Outlook

The stock appreciation rights are subject to vesting requirements and will be settled in shares of Pfizer common stock on the fifth and seventh anniversary of the grant date.

Industry Context

Stock appreciation rights are a common form of executive compensation in the pharmaceutical industry, aligning executive incentives with shareholder value by rewarding increases in the company's stock price.

Comparison to Industry Standards

• Companies like Johnson & Johnson (JNJ) and Merck & Co. (MRK) also utilize stock appreciation rights as part of their executive compensation packages.
• The vesting schedules and settlement terms are generally comparable to industry norms, with vesting periods typically ranging from three to five years.
• The specific number of SARs granted and the exercise price are determined based on individual performance and company valuation metrics, aligning with standard practices.

Stakeholder Impact

• The acquisition of stock appreciation rights aligns the executive's interests with those of shareholders, incentivizing them to increase shareholder value.

Key Dates